The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
IMS 2023 | Treatment options for patients with multiple myeloma refractory to lenalidomide
Wee Joo Chng, MB ChB, MRCP, MRCPath, PhD, National University of Singapore, Singapore, shares insights into treatment options available to patients with lenalidomide-refractory multiple myeloma. Prof. Chng discusses the role of various triplet regimens, including isatuximab, carfilzomib and dexamethasone (Isa-Kd), and pomalidomide, bortezomib and dexamethasone (PVd), and concludes by highlighting the value of novel CAR-T therapies and bispecific T-cell engagers (BiTEs) in these patients. This interview took place at the 20th International Myeloma Society (IMS) Annual Meeting, held in Athens, Greece.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
